- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
» Home » Drug Database » morphine
ADVERTISEMENT
ADVERTISEMENT
» Home » Drug Database » morphine
Brand Name :
Astramorph, Infumorph, Kadian, Mitigo, MS Contin
Synonyms :
Class :
Opioid analgesics
No drug interaction found for morphine and .
The interaction may increase the risk of sedation, respiratory depression, and coma
The interaction may increase the risk of sedation, respiratory depression, and coma
The interaction may increase the risk of sedation, respiratory depression, and coma
The interaction may increase the risk of sedation, respiratory depression, and coma
The interaction may increase the risk of sedation, respiratory depression, and coma
Concurrent use within 14 days after pholcodine treatment may lead to serotonin syndrome
may increase the depressant effect of opioid agonists
may increase the depressant effect of opioid agonists
may increase the depressant effect of opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
morphine (Systemic): they may decrease the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors)
morphine (Systemic): they may decrease the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors)
morphine (Systemic): they may decrease the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors)
morphine (Systemic): they may decrease the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors)
morphine (Systemic): they may decrease the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors)
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may increase the depressant effect of opioid agonists
may increase the depressant effect of opioid agonists
may increase the depressant effect of opioid agonists
may reduce the serum concentration of anti-platelet agents
may enhance the serum concentration
may increase the CNS depressant effect
may increase the CNS depressant effect of CNS depressants
acrivastine and pseudoephedrine
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increasingly adverse effect when combined with alvimopan
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
It may increase the arrhythmogenic effect when combined with epinephrine (Systemic)
may increase the CNS depressant effect of CNS Depressants
acetaminophen/doxylamine/dextromethorphan
may increase the CNS depressant effect CNS Depressants
may increase the toxic effect of each other when combined
nalmefene: they may decrease the therapeutic effect of opioid drug
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
may have an increased Effect of CNS depressant when combined with serotonergic opioids
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
The interaction may enhance the risk of anaphylaxis
The interaction may enhance the risk of anaphylaxis
The interaction may enhance the risk of anaphylaxis
The interaction may enhance the risk of anaphylaxis
The interaction may enhance the risk of anaphylaxis
they decrease the effect of analgesia of opioid agonists
they decrease the effect of analgesia of opioid agonists
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
may diminish the analgesic effect when combined with opioid agonists
may diminish the analgesic effect when combined with opioid agonists
may diminish the analgesic effect when combined with opioid agonists
may diminish the analgesic effect when combined with opioid agonists
it increases the effect of CNS depressants
may decrease the therapeutic effect of opioids
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
may decrease the analgesic effect of opioids
may have an increased constipating effect when combined with eluxadoline
may decrease the therapeutic effect when combined with opioid agonists
methylnaltrexone: they may increase the adverse effect of opioid antagonists
samidorphan: they may decrease the therapeutic effect of opioid agonists
may decrease the therapeutic effect of Nalmefene
may diminish the analgesic effect when combined with opioid agonists
may diminish the analgesic effect when combined with opioid agonists
may diminish the analgesic effect when combined with opioid agonists
may diminish the analgesic effect when combined with opioid agonists
the efficacy of dopamine agonists is decreased with methotrimeprazine when combined
It may lead to sedation, respiratory depression, and coma
It may lead to sedation, respiratory depression, and coma
It may lead to sedation, respiratory depression, and coma
It may lead to sedation, respiratory depression, and coma
It may lead to sedation, respiratory depression, and coma
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
may enhance the adverse/toxic effect of diuretics
may enhance the adverse/toxic effect of diuretics
may enhance the adverse/toxic effect of diuretics
may enhance the adverse/toxic effect of diuretics
may enhance the adverse/toxic effect of diuretics
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
It may enhance the metabolism when combined with dexamethasone
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
spironolactone and hydrochlorothiazide
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
spironolactone and hydrochlorothiazide
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
may have an increased analgesic effect when combined with opioid agonists
may have an increased analgesic effect when combined with opioid agonists
may have an increased analgesic effect when combined with opioid agonists
may have an increased analgesic effect when combined with opioid agonists
may have an increased analgesic effect when combined with opioid agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
acetaminophen/dextromethorphan/pseudoephedrine/guaifenesin
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
brompheniramine, dextromethorphan and phenylephrine
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with inorganic compounds
It may enhance the risk of adverse effects when combined with inorganic compounds
It may enhance the risk of adverse effects when combined with inorganic compounds
when used with dronabinol increases the CNS suppression
it may reduce the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of gastrointestinal agents
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
anticholinergic agents may enhance the adverse/toxic effect of opioid agonists
anticholinergic agents may enhance the adverse/toxic effect of opioid agonists
anticholinergic agents may enhance the adverse/toxic effect of opioid agonists
anticholinergic agents may enhance the adverse/toxic effect of opioid agonists
anticholinergic agents may enhance the adverse/toxic effect of opioid agonists
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
CNS depressants increase the CNS depressing effect of alcohol
may increase the CNS depressant effect of opioid agonists
may increase the CNS depressant effect of opioid agonists
may increase the CNS depressant effect of opioid agonists
may increase the CNS depressant effect of opioid agonists
may increase the CNS depressant effect of opioid agonists
may increase the CNS depressant effect
may enhance the risk of adverse/toxic effect of alvimopan
may enhance the adverse/toxic effect of naloxegol
may increase the analgesic effect of opioid agonists
may increase the toxic effects of opioid agonists
may increase the toxic effects of opioid agonists
may increase the toxic effects of opioid agonists
may increase the toxic effects of opioid agonists
may increase the toxic effects of opioid agonists
may increase the CNS depressant effect
may decrease the therapeutic activity of opioid agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the risk of adverse effect of Opioid agonists
may enhance the risk of adverse effect of Opioid agonists
may enhance the risk of adverse effect of Opioid agonists
may enhance the risk of adverse effect of Opioid agonists
may enhance the risk of adverse effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may increase the hypotensive effect of calcium channel blockers
may decrease the therapeutic effect of anticholinergic agents
may increase the arrhythmogenic effect of Inhalational Anaesthetics
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may increase the toxic effect of Anticholinergic Agents
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
pegvisomant: they may decrease the therapeutic effect of opioid agonists
ramosetron: they may increase the constipating effect of opioid drugs
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the risk of adverse effects of opioid agonists
may increase the risk of adverse effects of opioid agonists
may increase the risk of adverse effects of opioid agonists
may increase the risk of adverse effects of opioid agonists
may increase the risk of adverse effects of opioid agonists
may increase the risk of adverse effects of opioid agonists
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may increase the analgesic effect of opioid agonists
may increase the analgesic effect of opioid agonists
may increase the analgesic effect of opioid agonists
may increase the analgesic effect of opioid agonists
may increase the analgesic effect of opioid agonists
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may enhance the levels of serum concentration
may enhance the levels of serum concentration
may enhance the levels of serum concentration
may enhance the levels of serum concentration
may enhance the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
spironolactone and hydrochlorothiazide
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
amphetamines: they may increase the analgesic effect of opioid drugs
desmopressin: they may increase the toxic effect of opioid drugs
nitric oxide: they may increase the toxic effect of opioid drugs
succinylcholine: they may increase the bradycardic effect of opioid drugs
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
the side effects of dopamine agonists are increased with bromopride when combined
side effects of dopamine agonists are increased with solriamfetol when combined
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists serotonergic opioids
CNS depressants increase the effect of opioid agonists serotonergic opioids
CNS depressants increase the effect of opioid agonists serotonergic opioids
tricyclic antidepressants increase the CNS depression effect of serotonergic opioids
CNS depressants increase the effect of oxycodone
>10%
Pruritus
Urinary retention
Constipation
Headache
Somnolence
1-10%
Abdominal pain
Asthenia
Backache
Depression
Diarrhea
Dyspnea
Fever
Insomnia
Loss of appetite
Nausea
Paresthesia
Peripheral edema
Rash
Sweating
Xerostomia
Respiratory depression
Anxiety
Dizziness
Abnormal liver function test results
Amblyopia
Hiccups
Orthostatic hypotension
Syncope
Urinary retention
<1%
Respiratory depression
Frequency Not Defined
Anaphylaxis
Cardiac arrest
Circulatory depression
Ileus
Lightheadedness
Miosis
Malaise
Thinking disturbances
Myoclonus
Vertigo
Shock
Morphine is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.
Pregnancy consideration:
The drug is not meant for prolonged use during pregnancy.
Breastfeeding warnings:
Morphine is secreted in breast milk.
Pregnancy category:
Patient information leaflet
Generic Name: morphine
Pronounced: mor-feen
Why do we use morphine?
Morphine treats acute and chronic pain.
ADVERTISEMENT
» Home » Drug Database » morphine
Brand Name :
Astramorph, Infumorph, Kadian, Mitigo, MS Contin
Synonyms :
Class :
Opioid analgesics
Dosage forms & Strengths:
Adult:
Injectable solution:
0.5 mg/ml
1 mg/ml
Tablet:
15 mg
30 mg
Capsule:
10 mg
20 mg
30 mg
40 mg
50 mg
60 mg
Suppository:
10 mg
20 mg
30 mg
